Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 18.1% from a year ago
Total equity stood at $335.83M at the end of Q1 FY2026, up 18.1% from a year earlier and up 38.7% from the prior quarter.
Context
- Total equity amounted to 44.9% of total assets at the end of Q1 FY2026, down 40.3 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +18.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 242.14M USD
- Year-over-year change
- -22.5%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 242.14M | -22.5% |
| FY2024 | 2024-12-31 | 312.46M | +238.4% |
| FY2023 | 2023-12-31 | (225.72M) | -17.4% |
| FY2022 | 2022-12-31 | (192.29M) | — |
Total Equity vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 total equity of $335.83M is the 2nd highest of the 8 companies compared; the peer median is $204.53M.
- Its year-over-year change of +18.1% is the 3rd highest of 8, against a peer median of -16.1%.
- Total equity amounts to 44.9% of total assets for ZBIO, versus a peer median of 77.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $656.95M | +26.4% | +33.0% | 86.3% | |
| Mar 2026 | $335.83M | +18.1% | — | 44.9% | |
UPBUpstream Bio, Inc. | Mar 2026 | $304M | -31.8% | — | 95.6% |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $257.46M | -34.3% | — | 88.6% |
| Mar 2026 | $204.53M | -16.1% | -2.9% | 77.8% | |
| Mar 2026 | $143.65M | -0.3% | -19.5% | 72.3% | |
| Mar 2026 | $46.31M | +1253.8% | — | 72.7% | |
| Dec 2025 | $52K | -98.7% | -86.1% | 0.5% | |
| Peer median (excluding ZBIO) | $204.53M | -16.1% | -11.2% | 77.8% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.